Literature DB >> 3501311

Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins.

F E Katz1, G Janossy, A Cumber, W Ross, H A Blacklock, W Tax, P E Thorpe.   

Abstract

Four anti-T cell monoclonal antibodies were coupled to ricin-A and tested for their ability to kill T cells in peripheral blood and bone marrow using a clonogenic assay to quantify T cell survival. The immunotoxins (IT) prepared from RFT11 (CD2) and WT1 (CD7) antibodies were the most toxic to peripheral blood T cells. The immunotoxin prepared from RFT1 (CD5) was the next most efficient toxin and the immunotoxin prepared from RFT8 (CD8) was the least toxic. When these reagents were applied to peripheral blood cells at 3 x 10(-8) M the number of T cell colonies was reduced by an average of 95%, 94%, 84% and 50%, respectively. Peripheral blood T cells from different donors showed marked variability in their sensitivity to ITs. However, a cocktail of three ITs prepared from RFT11, WT1 and RFT1 gave superior and consistent killing (mean 99.9%; range 99.8-100%) of peripheral blood T cells from six donors. When this cocktail was applied to bone marrow cells from six donors, an average of 99.6% (range 99.5-99.8%) of the T cells were killed. Under the same conditions there was little or no reduction in the number of normal haematopoietic progenitors (CFU-GM, CFU-GEMM, CFU-Meg and BFU-E).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501311     DOI: 10.1111/j.1365-2141.1987.tb06161.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.

Authors:  Tie Fu Liu; Kimberly A Cohen; Mark C Willingham; Stephen B Tatter; Raj K Puri; Arthur E Frankel
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

3.  Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.

Authors:  C S Ramsden; M T Drayson; E B Bell
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

4.  Mutational analysis of the CD2/CD58 interaction: the binding site for CD58 lies on one face of the first domain of human CD2.

Authors:  C Somoza; P C Driscoll; J G Cyster; A F Williams
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.